Watch MED. Know when insiders buy.
One email the day a filing lands. Free.
Work order
42
WATCH · insiders 80, shorts 3
Insiders, 90 days
+$1.4M
net buying · 8 buys, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $141.2MP/E —DIV YIELD —FCF YIELD 2.84%REV TTM $316.9M −34.0%NET INCOME −$25.6M −803.7%NET CASH $71.9M52W 9.45 – 14.57NEXT EARNINGS Nov 9SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $76.4M | −27.6% | 69.9% | −$4.3M | −$3.1M | −225.0% | -0.28 | $1.7M | $969K | $728K | Aug 3 |
| Q1 2026 · Mar 31 | $76M | −34.3% | 68.1% | −$3.3M | −$2.1M | — | -0.19 | $260K | $1.1M | −$836K | Aug 3 |
| Q4 2025 · Dec 31derived | $75.1M | −36.9% | 69.4% | −$7.8M | −$18.1M | −2362.0% | -1.65 | −$5.3M | $1.4M | −$6.6M | Feb 17 |
| Q3 2025 · Sep 30 | $89.4M | −36.2% | 69.5% | −$4.1M | −$2.3M | −300.3% | -0.21 | $12.1M | $1.4M | $10.8M | Nov 3 |
| Q2 2025 · Jun 30 | $105.6M | −37.4% | 72.6% | −$1.1M | $2.5M | — | 0.22 | −$3.4M | $1.4M | −$4.8M | Aug 3 |
| Q1 2025 · Mar 31 | $115.7M | −33.8% | 72.8% | −$1.3M | −$772K | −109.3% | -0.07 | $3.4M | $1.5M | $1.9M | Aug 3 |
| Q4 2024 · Dec 31derived | $119M | −37.7% | 74.1% | $709K | $801K | −86.7% | 0.07 | −$4.9M | $2.3M | −$7.2M | Feb 17 |
| Q3 2024 · Sep 30 | $140.2M | −40.6% | 75.4% | $2.1M | $1.1M | −95.1% | 0.10 | $9.1M | $1.4M | $7.7M | Nov 3 |
| Q2 2024 · Jun 30 | $168.6M | — | 73.2% | −$7.9M | −$8.2M | — | -0.75 | $13.1M | $1.9M | $11.1M | Nov 3 |
| Q1 2024 · Mar 31 | $174.7M | — | 72.8% | $7.9M | $8.3M | — | 0.76 | $7.3M | $1.8M | $5.4M | Nov 3 |
| Q4 2023 · Dec 31derived | $191M | — | 74.0% | $8.7M | $6M | — | 0.55 | $10.5M | $946K | $9.6M | Feb 17 |
| Q3 2023 · Sep 30 | $235.9M | — | 75.2% | $25.5M | $23.1M | — | 2.12 | $29.9M | $1.7M | $28.3M | Nov 4 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $385.8M | 71.3% | −$14.2M | −$18.7M | -4.8% | -1.70 | $6.9M | $5.6M | $1.2M | $0 | $195K |
| FY2024 · to Dec 31 | $602.5M | 73.8% | $2.9M | $2.1M | 0.3% | 0.19 | $24.5M | $7.5M | $17M | $0 | $715K |
| FY2023 · to Dec 31 | $1.1B | 72.4% | $126.4M | $99.4M | 9.3% | 9.10 | $147.7M | $6.5M | $141.2M | $3.6M | $73M |
| FY2022 · to Dec 31 | $1.6B | 71.3% | $184.8M | $143.6M | 9.0% | 12.73 | $194.6M | $16.7M | $177.9M | $126.4M | $71.6M |
| FY2021 · to Dec 31 | $1.5B | 73.9% | $216.2M | $164M | 10.7% | 13.89 | $94.5M | $34.2M | $60.3M | $56M | $63.9M |
| FY2020 · to Dec 31 | $934.8M | 74.6% | $134.2M | $102.9M | 11.0% | 8.68 | $145.2M | $5.9M | $139.3M | $5M | $53.2M |
Every number comes from MEDIFAST INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.